Our study noted a decline in AF ablation-related hospitalizations and complications associated with the procedure. These findings largely reflect shifting trends of outpatient performance of the procedure and increasing safety profile due to improved institutional expertise and catheter techniques.
Background: In the last decade, the proportion of people with asthma in the USA grew by nearly 15%, with 479,300 hospitalizations and 1.9 million emergency department visits in 2009 alone. The primary objective of our study was to evaluate in-hospital outcomes in patients admitted with asthma exacerbation in terms of mortality, length of stay (LOS) and hospitalization costs. Methods: We queried the HCUP's Nationwide Inpatient Sample (NIS) between 2001 and 2010 using the ICD9-CM diagnosis code 493 for asthma (n = 760,418 patients). The NIS represents 20% of all hospitals in the USA. Multivariate logistic regression analysis was used to evaluate predictors of in-hospital mortality. LOS and hospitalization costs were also analyzed. Results: The overall LOS was 3.9 days and as high as 8.3 days in patients requiring mechanical ventilation. LOS has decreased in recent years, though it continues to be higher than in 2001. The hospitalization cost increased steadily over the study period. The overall in-hospital mortality was 1% and as high as 9.8% in patients requiring mechanical ventilation. Multivariate predictors of longer LOS, higher hospitalization costs and in-hospital mortality included increasing age and hospitalizations during the winter months. Private insurance was predictive of lower hospitalization costs and LOS as well as lower in-hospital mortality. Conclusion: Asthma continues to account for significant in-hospital mortality and resource utilization, especially in mechanically ventilated patients. Age, admissions during winter months and the type of insurance are independent predictors of in-hospital outcomes.
Background
There are limited data on the role of temporary mechanical circulatory support (
MCS
) devices for cardiogenic shock before left ventricular assist device (
LVAD
) surgery. This study sought to evaluate the trends of use and outcomes of
MCS
in cardiogenic shock before
LVAD
surgery.
Methods and Results
This was a retrospective cohort study from 2005 to 2014 using the National Inpatient Sample (20% stratified sample of US hospitals). This study identified admissions undergoing
LVAD
surgery with preoperative cardiogenic shock. Admissions for other cardiac surgery and heart transplant were excluded. Temporary
MCS
was identified using administrative codes. The primary outcome was hospital mortality and secondary outcomes were hospital costs and lengths of stay in admissions with and without
MCS
use. In this 10‐year period, 9753 admissions were identified with 40.6% requiring pre‐
LVAD MCS
. There was a temporal increase in the frequency of cardiogenic shock associated with an increase in non–intra‐aortic balloon pump
MCS
devices. The cohort receiving
MCS
had greater in‐hospital myocardial infarction, ventricular arrhythmias, and use of coronary angiography. On multivariable analysis, older age, myocardial infarction, and need for
MCS
devices were independently predictive of higher in‐hospital mortality. In 696 propensity‐matched pairs, use of
MCS
was predictive of higher in‐hospital mortality (odds ratio 1.4 [95% confidence interval 1.1–1.6];
P
=0.02) and higher hospital costs, but similar lengths of stay.
Conclusions
In patients with cardiogenic shock bridged to
LVAD
therapy, there was a steady increase in preoperative
MCS
use. Use of
MCS
identified patients at higher risk for in‐hospital mortality and greater resource utilization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.